Glutathione for liver health is an idea with a real starting point in biochemistry. The question is whether that biochemistry has been turned into evidence that taking glutathione helps a damaged liver, and so far the answer rests on a handful of small studies without control groups.
Why the liver and glutathione are linked
Glutathione is a three-amino-acid peptide present in every cell, built from glutamic acid, cysteine and glycine, and it is central to the systems cells use to detoxify chemicals and resist oxidative damage [1]. When the liver breaks down certain drugs it can produce reactive byproducts, and glutathione is one of the molecules that binds them before they injure liver cells.
The clearest case is acetaminophen overdose. The approved antidote is acetylcysteine, given by vein, and its label says it probably protects the liver by maintaining or restoring glutathione levels, or by standing in for glutathione in neutralizing acetaminophen’s reactive metabolite [5]. Acetylcysteine supplies cysteine, which the body then builds into glutathione.
That is the strongest link between glutathione and the liver, and it is worth being precise about what it shows. It shows that restoring the liver’s own glutathione, through a precursor, limits one kind of acute injury. It does not show that swallowing or injecting glutathione itself treats a chronic liver disease, which is where the claims for glutathione products usually point.
The first hurdle: getting glutathione into the body
Oral glutathione was long assumed to be broken down in the gut into its three amino acids, which would make it no different from eating protein [1]. A 6-month randomized trial in 54 healthy adults challenged that: at 250 or 1,000 mg a day, glutathione levels in blood rose from the first month, and in most measures they returned to baseline after a 1-month washout [6].
That trial measured blood and immune cells, not the liver, so it tells you glutathione from a capsule can reach the circulation, not that it reaches liver cells in useful amounts. The absorption question is covered in more depth in liposomal glutathione, and the amounts each trial used in glutathione dosage.
What the fatty-liver studies found
The best-documented human study is a Japanese multicenter pilot in people with nonalcoholic fatty liver disease diagnosed by ultrasound [1]. Everyone first spent 3 months on a diet and exercise program, and then took 300 mg of oral glutathione a day for 4 months. The primary outcome was the change in ALT, a liver enzyme that rises when liver cells are injured.
68.9 → 58.1
mean ALT, IU/L, before and after 4 months of glutathione (p = 0.014), 29 patients
Honda 2017
295.7 → 285.4
liver fat by CAP, dB/m, not a significant change (p = 0.07)
Honda 2017
12.9%
median fall in ALT, used to split responders from non-responders
Honda 2017
Of 32 people who started glutathione, 29 finished, and three stopped, one each for fatigue, raised blood pressure and a rash [1]. Triglycerides and ferritin also fell. Liver stiffness, a marker of scarring, did not change significantly. Liver fat did fall in the 15 people whose ALT dropped by at least the median, a group that was younger and had less diabetes than the rest.
The authors list the limits themselves: a single arm with no control group, a small sample and a short treatment period. Because the lifestyle program ran first, some of the ALT change could reflect diet and exercise continuing to work, and a single-arm design cannot separate the two.
A second Japanese pilot gave the same 300 mg a day by mouth for 3 months to 15 people, 10 with steatohepatitis (NASH) and 5 with simple fatty liver [2]. ALT and 8-OHdG, a blood marker of oxidative DNA damage, fell significantly in the NASH group, while the change in the enzyme GGT was not significant.
| Study | Who | What the study used | Design | Liver result |
|---|---|---|---|---|
| Honda 2017, Japan | 29 completers with NAFLD | 300 mg oral daily, 4 months, after 3 months of lifestyle change | Single-arm, open-label | ALT fell; liver fat and stiffness not significant |
| Irie 2016, Japan | 10 with NASH, 5 with fatty liver | 300 mg oral daily, 3 months | Single-arm | ALT and 8-OHdG fell in the NASH group |
| Dentico 1995, Italy | Chronic fatty liver disease | Up to 1,800 mg a day by vein | Abstract only (article in Italian) | Liver tests improved, per the abstract |
A 2025 literature review of glutathione therapy in fatty liver disease looked for human studies from 2014 to 2024 and found three, with 109 participants in total [3]. All three were single-arm, all ran in Japan or India, and the reviewers concluded that small samples and inconsistent protocols limit what can be generalized and that large randomized trials are still needed.
Intravenous glutathione
Glutathione has been given by vein for chronic liver disease and for poisoning, as the Japanese pilot’s authors note [1]. An Italian report from 1995, available to English readers only as an abstract, described high-dose IV glutathione in chronic fatty liver disease improving liver tests, and favored 1,800 mg a day [4]. The abstract gives no group sizes or comparison, so it cannot be weighed like a trial.
How IV glutathione products are made and what FDA has flagged about them is covered in glutathione injections, and the adverse events reported by route in glutathione side effects.
What this means if you are considering glutathione
Glutathione is compounded under FDA's interim policy for 503A Category 1 substances, so it can be prescribed, but no product carries a liver indication. [7] If liver health is the reason you are interested, the fatty-liver studies point to one practical conclusion: the diet-and-exercise phase that preceded glutathione in the best-documented study is the part with established evidence behind it.
If you already have a liver condition, whether glutathione fits alongside its treatment is a question for the clinician who manages it. Prescribers of glutathione and NAD+ are ranked together on the longevity board, and the Synergy Rx review covers one seller that offers glutathione as an injection. NAD+ doses from human studies are set out in NAD dosage, and more options sit on the longevity goal page. Its place among the peptides studied for inflammation is covered in peptides for inflammation.